MBX Biosciences (MBX) Shares Outstanding (Diluted Average) (2023 - 2026)
MBX Biosciences' (MBX) quarterly Shares Outstanding (Diluted Average) came in at $46.6 million in Q1 2026, up 39.4% year-on-year from $33.4 million in Q1 2025, and up 27.58% quarter-over-quarter from $36.5 million in Q4 2025.
MBX Biosciences (MBX) Shares Outstanding (Diluted Average) (2023 - 2026) Analysis & Trends
MBX Biosciences has disclosed Shares Outstanding (Diluted Average) across 4 years of filings, most recently posting $46.6 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $46.6 million, up 39.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.6 million (up 39.4% YoY), and the FY2025 annual result was $36.5 million, up 243.01% from the prior year.
- Shares Outstanding (Diluted Average) came in at $46.6 million for Q1 2026 at MBX Biosciences, up from $36.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $46.6 million in Q1 2026 to a low of $1.0 million in Q4 2023.
- The 4-year median for Shares Outstanding (Diluted Average) is $10.6 million (2024), against an average of $18.3 million.
- Across the five-year window, Shares Outstanding (Diluted Average) jumped 2678.82% in 2025 and jumped 39.4% in 2026, its largest moves.
- MBX Biosciences' Shares Outstanding (Diluted Average) stood at $1.0 million in 2023, then soared by 944.7% to $10.6 million in 2024, then jumped by 243.01% to $36.5 million in 2025, then advanced by 27.58% to $46.6 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $46.6 million (Q1 2026), $36.5 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 92.44 Mn |
| 10 | MBX Biosciences | 1.44 Bn | 1.44 Bn | - | 46.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.58 Mn |
| Dec 31, 2025 | 36.51 Mn |
| Sep 30, 2025 | 33.69 Mn |
| Jun 30, 2025 | 33.45 Mn |
| Mar 31, 2025 | 33.41 Mn |
| Dec 31, 2024 | 10.64 Mn |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 1.08 Mn |